Abstract

Simple SummarySurvival of ovarian cancer patients largely relies on the surgical removal of all cancer cells. To achieve this, good vision is crucial. In this study, we evaluate the ability of hyperspectral imaging to detect ovarian cancer. Images of surgically removed tissue samples of 11 patients were taken and compared to histopathology in order to train machine learning software. For training purposes, only healthy tissues and tissues with high tumor cell content (>50%) were included. In total, 26 tissue samples and 26,446 data points of 10 patients were included. Tissue classification as either tumorous or healthy was evaluated by leave-one-out cross-validation. This resulted in a power of 0.83, a sensitivity of 0.81, a specificity of 0.70 and a Matthew’s correlation coefficient of 0.41. To conclude, this study shows that hyperspectral imaging can be used to recognize ovarian cancer. In the future, the technique may enable real-time image guidance during surgery.The most important prognostic factor for the survival of advanced-stage epithelial ovarian cancer (EOC) is the completeness of cytoreductive surgery (CRS). Therefore, an intraoperative technique to detect microscopic tumors would be of great value. The aim of this pilot study is to assess the feasibility of near-infrared hyperspectral imaging (HSI) for EOC detection in ex vivo tissue samples. Images were collected during CRS in 11 patients in the wavelength range of 665–975 nm, and processed by calibration, normalization, and noise filtering. A linear support vector machine (SVM) was employed to classify healthy and tumorous tissue (defined as >50% tumor cells). Classifier performance was evaluated using leave-one-out cross-validation. Images of 26 tissue samples from 10 patients were included, containing 26,446 data points that were matched to histopathology. Tumorous tissue could be classified with an area under the curve of 0.83, a sensitivity of 0.81, a specificity of 0.70, and Matthew’s correlation coefficient of 0.41. This study paves the way to in vivo and intraoperative use of HSI during CRS. Hyperspectral imaging can scan a whole tissue surface in a fast and non-contact way. Our pilot study demonstrates that HSI and SVM learning can be used to discriminate EOC from surrounding tissue.

Highlights

  • Invisible and non-palpable tumors could be detected during surgery, progression-free and overall survival could increase [5]

  • The variations of the classification power could be explained by the non-homogeneous distribution of the tumor tissue and the types of healthy tissue across the patients, which influenced the training dataset for the support vector machine (SVM) classifier

  • Our pilot study shows that hyperspectral imaging (HSI) is a promising technique for detecting tumors

Read more

Summary

Introduction

Ovarian cancer is the number eight cause of cancer-related mortality in women around the world, with an incidence of 314,000 and mortality of 207,000 in 2020 [1]. Since early warning signs are often vague or missing, ovarian cancer is often detected in late stages (FIGO IIB–IV) [3]. The standard therapy for advanced-stage ovarian cancer is complete cytoreductive surgery (CRS) of all visible tumors and six cycles of chemotherapy [3,4]. Complete resection of all macroscopic disease is the strongest independent variable in predicting overall survival. Even after complete CRS and removal of all visible and palpable tumors, women with advanced epithelial ovarian cancer can experience recurrence, possibly as a result of microscopic residual tumors. Invisible and non-palpable tumors could be detected during surgery, progression-free and overall survival could increase [5]. When no microscopic tumor is detected, healthy tissue can be spared, potentially shortening the duration of surgery and recovery

Objectives
Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call